SCHEMBL9927441

SCHEMBL9927441

O=S(=O)(Nc1ccc(Cl)cc1Cl)c1ccc2ccccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.56
HPGD P15428 2/20 0.55
TSHR P16473 1/20 0.55
MCL1 Q07820 1/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
ALDH1A1 P00352 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
GLO1 Q04760 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
ATM Q13315 1/20 0.51
ERBB2 P04626 1/20 0.51
HSP90AA1 P07900 1/20 0.51
HSP90AB1 P08238 1/20 0.51
KAT6A Q92794 2/20 0.51
PLAU P00749 1/20 0.51
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
GPR27 Q9NS67 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28561899 0.89 HPGD (0.50) HPGDTSHRMCL1ERBB2HSP90AA1
SCHEMBL10013441 0.86 MEN1 (0.60) HPGDMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL28878201 0.83 WDR5 (0.64) FBP1HPGDMEN1KMT2AALDH1A1
SCHEMBL11027219 0.83 ERBB2 (0.71) HPGDTSHRMCL1MEN1KMT2A
SCHEMBL9931416 0.78 CCR2 (0.71)
SCHEMBL16210882 0.77 MEN1 (0.59) HPGDMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL28913966 0.77 CCR2 (0.65) HPGDTSHRMCL1ALDH1A1ERBB2
SCHEMBL4874851 0.77 CCR2 (0.65) HPGDTSHRMCL1ERBB2HSP90AA1
SCHEMBL7182449 0.77 APP (0.64) HPGDTSHRMCL1MEN1KMT2A
SCHEMBL7578178 0.75 PTGES2 (0.64) MCL1MEN1KMT2AALDH1A1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRPC4, TRPC1, TRPC3 FBP1 4230/4885HPGD 4259/4885TSHR 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.